Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23555501 | 0.86 | MAPK1 (0.37) | GLP1R | |
| SCHEMBL26807017 | 0.86 | GLP1R (0.44) | GLP1R | |
| SCHEMBL22566705 | 0.81 | GLP1R (0.46) | GLP1R | |
| SCHEMBL18715475 | 0.80 | GLP1R (0.48) | GLP1R | |
| SCHEMBL23555894 | 0.74 | MAPK1 (0.39) | GLP1R | |
| SCHEMBL20857186 | 0.72 | MAPK1 (0.40) | GLP1R | |
| SCHEMBL21148565 | 0.72 | MAPK1 (0.45) | GLP1R | |
| SCHEMBL22455037 | 0.68 | GLP1R (0.38) | GLP1R | |
| SCHEMBL19325102 | 0.68 | MAPK1 (0.42) | GLP1R | |
| SCHEMBL20800942 | 0.68 | GLP1R (0.42) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11534453-B2 | RNAi therapy for hepatitis B virus infection | Arrowhead Pharmaceuticals, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11534453-B2 | RNAi therapy for hepatitis B virus infection | HAVCR2, NR1H4, SRRT | GLP1R 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.